MECOM融合伴侣与骨髓原始细胞比例影响MECOM重排急性髓系白血病患者的结局
该研究纳入152例初诊MECOM重排急性髓系白血病成人患者,按骨髓原始细胞比例(<20% vs ≥20%)和融合伴侣(经典GATA2::MECOM vs 变异型)分组,分析总生存。≥20%原始细胞与更差总生存独立相关(HR 1.9),在<20%原始细胞患者中变异型融合伴侣与死亡风险降低独立相关(HR 0.2)。MECOM重排急性髓系白血病具有异质性,应考虑低强度治疗。
要点
- ≥20%骨髓原始细胞是MECOM重排急性髓系白血病总生存的独立不良因素(HR 1.9)。
- 在<20%原始细胞患者中,变异型MECOM融合伴侣与死亡风险降低独立相关(HR 0.2)。
- MECOM重排急性髓系白血病具有异质性,作者认为应考虑低强度治疗。
核心结论
- MECOM重排急性髓系白血病是一种异质性疾病,骨髓原始细胞比例和MECOM融合伴侣与总生存相关。
- 作者认为应考虑低强度治疗。
研究设计与样本
- 研究纳入152例初诊MECOM重排急性髓系白血病成人患者。
- 按骨髓原始细胞比例分为<20%或≥20%,按MECOM融合伴侣分为经典(GATA2::MECOM)或变异型(其他)。
- 41%接受强化化疗,59%接受低强度治疗。
主要发现
- 31%患者骨髓原始细胞<20%,69%≥20%;57%为经典融合,43%为变异型融合。
- 强化化疗的复合完全缓解率为50%,低强度治疗为48%(p=0.99)。
- 骨髓原始细胞<20%患者的中位总生存为17个月(95%CI 12-不可估计),≥20%患者为9个月(95%CI 6-10)(p<0.01)。
- 多因素分析显示,≥20%原始细胞与更差总生存相关(HR 1.9,95%CI 1.2-3.2,p<0.01),独立于年龄、MECOM融合伴侣、额外细胞遗传学异常、治疗强度、加用维奈克拉和干细胞移植。
- 强化化疗的HR为2.0(95%CI 1.1-3.7,p=0.03);在<20%原始细胞患者中,变异型MECOM融合伴侣与死亡风险降低独立相关(HR 0.2,95%CI 0.1-0.8,p<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MECOM rearrangements (MECOM-r) are acute myeloid leukaemia (AML)-defining, regardless of blast percentage or MECOM fusion partner. We sought to investigate if blast percentage or MECOM-r partner was associated with overall survival (OS). We included 152 adult patients with newly diagnosed MECOM-r and classified blast percentage into <20% or ≥20% and MECOM-r partner into classic (GATA2::MECOM) or variant (others). Thirty-one per cent had <20% blasts, with 69% having ≥20%; 57% had classic and 43% variant MECOM-r. Treatment was with intensive chemotherapy (IC) in 41% and low-intensity therapy (LIT) in 59%. Composite complete remission rates were similar between IC (50%) and LIT (48%, p = 0.99). The median OS was 17 months (95% confidence interval [CI], 12-not estimable [NE]) for <20% blasts, compared with 9 months (95% CI, 6-10) for ≥20% blasts (p < 0.01). On multivariate analysis, ≥20% blasts were associated with worse OS (hazard ratio [HR] 1.9, [95% CI, 1.2-3.2], p < 0.01), independent of age, MECOM-r partner, additional cytogenetic abnormalities, treatment intensity, addition of venetoclax and stem cell transplant (SCT). HR for IC was 2.0 (95% CI, 1.1-3.7, p = 0.03). In <20% blasts, variant MECOM-r was independently associated with a reduced hazard of death (HR 0.2 [95% CI, 0.1-0.8], p < 0.01). MECOM-r AML is a heterogenous entity; consideration should be given to LIT approaches.
引用
- Jen WY, Tang G, Kugler E, et al. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. Br J Haematol. 2025. PMID: 40983567. doi:10.1111/bjh.70171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。